Literature DB >> 12212589

Treatment effects in patients with squamous cell carcinoma of the oral cavity.

Katsuhide Inagi1, Hiroomi Takahashi, Makito Okamoto, Meijin Nakayama, Tomohiro Makoshi, Hiromi Nagai.   

Abstract

A total of 221 patients (155 males, 66 females; stage I, n = 55: stage II, n = 58; stage III, n = 57; stage IV, n = 51) with squamous cell carcinoma of the oral cavity were studied. Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9. In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group. Five-year cumulative survival rates showed significant differences between stage classifications (stage I = 91%, stage II = 73%, stage III = 63%, stage IV = 47%; p < 0.01) but not between tumor sites. The 5-year cumulative survival rate was highest for oral floor cancer (80%). In the early-cancer group, the 5-year cumulative survival rate for the surgery group (92%) was significantly higher (p < 0.05) than those for both the radiation (69%) and combination (71%) groups. In the advanced-cancer group, the 5-year cumulative survival rate for the surgery group (74%) was significantly higher (p < 0.05) than those for both the radiation (37%) and combination (51%) groups. No significant difference in regional control rates was observed between the treatment groups. Five-year regional control rates were 86% for cervical untreated patients with T1N0 tumors and 60% for cervical untreated patients with T2N0 tumors. Fourteen N0 cases were treated with neck dissection. Cervical metastasis was found pathologically in 2/14 (14%) of these cases. The 5-year survival rate for patients with cervical recurrences after primary tumor resection was 70% (n = 15). In contrast, the 5-year survival rate for patients with both primary tumor resection and neck dissection was 74% (n = 14) but no significant difference was observed between these 2 groups.

Entities:  

Mesh:

Year:  2002        PMID: 12212589     DOI: 10.1080/000164802760057527

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  9 in total

1.  Escopoletin treatment induces apoptosis and arrests cell cycle at G0/G1 phase in the oral squamous cancer cell lines.

Authors:  Zhuo Wang; Hua-Yan Guo; Yuan-Liang Huang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma.

Authors:  Koji Harada; Takanori Takenawa; Tarannum Ferdous; Yasuhiro Kuramitsu; Yoshiya Ueyama
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

3.  High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.

Authors:  Koji Harada; Tarannum Ferdous; Toyoko Harada; Yoshiya Ueyama
Journal:  Clin Exp Med       Date:  2015-11-21       Impact factor: 3.984

4.  Value of intraoperative ultrasonography in tonsil cancer.

Authors:  Jakub Pazdrowski; Pieńkowski Piotr; Magdalena Kordylewska; Anna Wegner; Paweł Golusiński; Wojciech Golusiński
Journal:  Rep Pract Oncol Radiother       Date:  2010-05-20

5.  Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients.

Authors:  Baris Karakullukcu; Kim van Oudenaarde; Marcel P Copper; W M C Klop; Robert van Veen; Maarten Wildeman; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-13       Impact factor: 2.503

6.  Speech and swallowing outcomes in buccal mucosa carcinoma.

Authors:  Sunila John; Rashida M Hassuji; B Rajashekhar
Journal:  Indian J Palliat Care       Date:  2011-09

7.  Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.

Authors:  Ryota Yamanouchi; Koji Harada; Tarannum Ferdous; Yoshiya Ueyama
Journal:  Mol Clin Oncol       Date:  2018-01-10

Review 8.  Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.

Authors:  Koji Harada; Tarannum Ferdous; Yoshiya Ueyama
Journal:  Jpn Dent Sci Rev       Date:  2016-12-19

9.  Traditional Chinese medicine for oral squamous cell carcinoma: A Bayesian network meta-analysis protocol.

Authors:  Dong Wang; XiaoJie Duan; Yuhui Zhang; Zhen Meng; Jing Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.